OXFORD, U.K: Sensyne Health plc has signed a five year non-exclusive Strategic Research Agreement (SRA) with Great Ormond Street Hospital for Children NHS Foundation Trust (GOSH) to analyse anonymised patient data using clinical artificial intelligence (Clinical AI) technology.
The purpose of the SRA is to enable the ethical application of Clinical AI research to improve pediatric clinical outcomes, and accelerate research into new medicines to find new and better ways to treat rare and complex childhood diseases.
The SRA is Sensyne’s first to focus on improving care and accelerating the development of medicines specifically for children.
Ad Statistics
Times Displayed: 8061
Times Visited: 26 Brand-New FDA-cleared Advanced Ultrasound Medical Device available for sale or lease to Wound Care Centers or any other Medical Facilities.The Arobella 1000D is designed for non-contact or debridement ultrasound wound healing therapy, or any other wounds
The first project will focus on developing a clinical decision support algorithm to help clinicians caring for children with chronic kidney disease. This will then be used to develop further clinical support algorithms for other diseases in children.
Development of pediatric medicines, from discovery through clinical development, has long been especially challenging. Recent developments in Clinical AI and the use of real world data provide an opportunity to develop new medicines and to accelerate the clinical development of treatments for childhood illnesses. This will be a key focus of the research that Sensyne and GOSH will seek to develop.
Matthew Shaw, Chief Executive of Great Ormond Street Hospital, said: “At GOSH we treat patients with the most rare and complex conditions. Research into developing new diagnosis and treatments is vital and we are always looking to find ways to improve patient outcomes, while making sure their information is safe and secure.
Children are at the heart of everything we do and this collaboration is no different. It will offer the potential to use digital innovation to find and develop diagnosis and treatments much faster, not just for GOSH patients but children across the country and internationally.”
Lord (Paul) Drayson PhD, CEO of Sensyne Health, said: “We are delighted to be undertaking research in partnership with Great Ormond Street Hospital, widely recognised as one of the leading centres for children’s healthcare and research in the world. GOSH has invested heavily in its digital infrastructure and curation of its data which means we can start work immediately: together we aim to use the power of ethical AI to make a real difference in finding new and better ways to treat rare and complex childhood diseases and in future to develop a world-wide research community using ethical AI to improve the lives of children world-wide.”
